Fill out the form to access this resource. Already a registered customer? Sign in to access this resource.
New Horizons, Expanding Possibilities
Kristina Beeler, PhD (Biognosys)
Genomics and transcriptomics provide only a limited understanding of disease biology, which results in a significant stumbling block to the success of precision medicine. Proteomics has emerged as the method of choice to answer some of the most challenging questions across the drug development pipeline, from novel target discovery to large-scale biomarker studies. For almost 15 years, Biognosys has been at the leading-edge of proteomics. Over this time, we have developed industry-leading solutions that have enabled some of the most innovative biopharma companies to unlock discoveries and progress their drug development pipelines.